Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.
RU58841 is used by some for hair loss when finasteride and minoxidil are ineffective. Users report mixed results, with some experiencing side effects like chest pain and mood changes.
The user has seen marginal improvement in hair loss after increasing finasteride from 1 mg three times a week to daily and using minoxidil inconsistently. They plan to start microneedling and are considering using it on both their scalp and face.
The user is seeking help with using Ell-Cranell for hair loss treatment. They are unsure about the correct application method and dosage. They also inquire about combining microneedling with topical alfatradiol and question a study that referred to alfatradiol as a hair growth inhibitor in male mice.
Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.
The user is seeking an alternative to DualGen 15 that includes Minoxidil and Retinol but is less sticky and more convenient to use. They find the current product inconvenient due to its stickiness and long wait time before washing.
The user shared a 4-month hair loss treatment update, using Kirkland liquid minoxidil twice daily, microneedling with 1.5mm and 0.5mm needles, and applying rosemary oil twice a week. They plan to start taking finasteride and also grew a beard by microneedling and applying minoxidil to their face.
A user experienced significant hair regrowth using dutasteride without side effects, starting with finasteride and not using minoxidil or dermarolling. They attributed success to a unique genetic response to DHT blockers but did not share their full regimen, frustrating others.
The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
The conversation is about which blood markers to test before starting a 5-AR inhibitor for hair loss. The user mentions already testing Total T, Free T, SHBG, Estradiol, Haematocrit, Red blood cell count, and White cell count, and asks if DHT or additional markers are needed.
The user "AcanthocephalaNo7632" shared their progress with hair loss, mentioning the use of minoxidil and finasteride. Some users questioned the authenticity of the progress pictures.
The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
The conversation is about using a 0.5 mm dermaroller for microneedling alongside finasteride and minoxidil for hair loss treatment. The user seeks advice on different dermarollers and how often to replace them.
User shared progress pictures showing significant hair regrowth using 1mg finasteride and topical minoxidil daily since January. Other users congratulated and shared their own experiences and advice.
A user saw no results from using minoxidil and microneedling for 1.5 years and is considering trying tretinoin. They are seeking others' experiences with tretinoin for hair loss.
The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.
RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.
A user reported hair regrowth after 1.5 months of using topical minoxidil, finasteride, and dermarolling. Other users noted possible improvement but mentioned difficulty in assessing due to lighting and hair length differences.
The conversation is about using adenosine, finasteride, and minoxidil for hair loss treatment. The user ordered a 0.75% adenosine solution and is currently using finasteride 1mg and minoxidil 5%.
The user experienced significant hair regrowth after 7 months using topical minoxidil once a day and 0.5mg dutasteride every other day, with noticeable results in the last two to three months. They reported no side effects and did not use dermarolling.
A user maintains NW2 hair with 1mg finasteride, 2.5mg oral minoxidil, and 5% topical minoxidil twice daily, along with ketoconazole shampoo and derma stamping. They seek advice on more aggressive treatments to achieve NW1.
A 28-year-old male shares progress on hair loss treatment using 0.5mg dutasteride and 5mg minoxidil, experiencing initial shedding but encouraged by community support. He also uses ketoconazole occasionally based on scalp oiliness.
Clascoterone lotion, being tested in Germany, is as effective as Minoxidil and Finasteride for hair loss but without serious side effects. About 400 men participated in the trials.
A 21-year-old male shares progress pictures showing improvement in hair growth using daily topical minoxidil 5%, microneedling 1.25mm, and 500mg of saw palmetto. He reports new and healthy hair growth, indicating success in managing androgenic alopecia.
A user discusses using tazarotene to enhance minoxidil's effectiveness for hair regrowth, believing it will make a significant difference. Others caution about potential risks of retinoids accelerating hair loss in some individuals.